Celcuity Inc. (CELC) Launches REVTORPYK Commercially in U.S.

Celcuity said REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without a PIK3CA mutation, in combo with fulvestrant with or without palbociclib, following progression after at least one metastatic endocrine therapy.Material DetailsContext by AI…